Email: cspc@cspc.cn
Email: cspc@cspc.cn
September 23, 2022
“Lenalidomide Capsules (25mg)"developed by CSPC has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.
Lenalidomide is a new generation oral immunomodulatory drug with immunomodulatory, antiangiogenic, and antineoplastic properties. It is used to treat 1) in combination with dexamethasone, adult patients with previously untreated multiple myeloma who are not eligible for transplant; 2) in combination with dexamethasone, adult patients with multiple myeloma who have received at least one prior therapy. The approval of the Product will further enrich the Group’s product portfolio of antineoplastic drugs.
